Skip Navigation LinksHome > December 2013 - Volume 56 - Issue 4 > Osteoporosis Treatment and Prevention for Postmenopausal Wom...
Clinical Obstetrics & Gynecology:
doi: 10.1097/GRF.0b013e3182a9fb02
Osteoporosis: Diagnosis and Management

Osteoporosis Treatment and Prevention for Postmenopausal Women: Current and Future Therapeutic Options

PINKERTON, JOANN V. MD*; THOMAS, SEMARA MD*; DALKIN, ALAN C. MD

Collapse Box

Abstract

Osteoporosis, a “silent disease,” is often unrecognized until fracture. Lifestyle modification with nutritional counseling is recommended during menopausal transition. Bone density testing is recommended for women aged 65 years and older, younger postmenopausal women with risk factors, or to follow therapy. Bisphosphonates treat osteoporosis (prevent bone resorption). Raloxifene and hormone therapy prevent bone loss and fracture, with extraskeletal benefits. Denosumab treats osteoporosis, although bone effects reverse rapidly. Teriparatide (anabolic therapy) is considered for women at high risk of fracture. Bazedoxifene with conjugated estrogens, novel delivery of teriparatide, new parathyroid hormone proteins, anti-sclerostin antibodies, cathepsin K inhibitors, and stem cell therapies are in testing.

© 2013, Lippincott Williams & Wilkins

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.